Assessment of Vitamin D Metabolism in Patients with Cushing's Disease in Response to 150,000 IU Cholecalciferol Treatment.

In this study we aimed to assess vitamin D metabolism in patients with Cushing's disease (CD) compared to healthy individuals in the setting of bolus cholecalciferol treatment. The study group included 30 adults with active CD and the control group included 30 apparently healthy adults with similar age, sex and BMI. All participants received a single dose (150,000 IU) of cholecalciferol aqueous solution orally. Laboratory assessments including serum vitamin D metabolites (25(OH)D 3 , 25(OH)D 2 , 1,25(OH) 2 D 3 , 3-epi-25(OH)D 3 and 24,25(OH) 2 D 3 ), free 25(OH)D, vitamin D-binding protein (DBP) and parathyroid hormone (PTH) as well as serum and urine biochemical parameters were performed before the intake and on Days 1, 3 and 7 after the administration. All data were analyzed with non-parametric statistics. Patients with CD had similar to healthy controls 25(OH)D 3 levels ( p > 0.05) and higher 25(OH)D 3 /24,25(OH) 2 D 3 ratios ( p < 0.05) throughout the study. They also had lower baseline free 25(OH)D levels ( p < 0.05) despite similar DBP levels ( p > 0.05) and lower albumin levels ( p < 0.05); 24-h urinary free cortisol showed significant correlation with baseline 25(OH)D 3 /24,25(OH) 2 D 3 ratio (r = 0.36, p < 0.05). The increase in 25(OH)D 3 after cholecalciferol intake was similar in obese and non-obese states and lacked correlation with BMI ( p > 0.05) among patients with CD, as opposed to the control group. Overall, patients with CD have a consistently higher 25(OH)D 3 /24,25(OH) 2 D 3 ratio, which is indicative of a decrease in 24-hydroxylase activity. This altered activity of the principal vitamin D catabolism might influence the effectiveness of cholecalciferol treatment. The observed difference in baseline free 25(OH)D levels is not entirely clear and requires further study.